Which class of diabetes medication is considered weight neutral?

DPP-4 inhibitors are considered weight neutral because they tend to have a minimal impact on body weight in patients with diabetes. This class of medications works by increasing incretin levels, which helps to regulate glucose metabolism and enhance insulin secretion in response to meals. Importantly, DPP-4 inhibitors do not prompt significant weight gain or loss, making them a suitable choice for individuals where weight management is a concern as part of their diabetes treatment plan.

The other classes, such as SGLT-2 inhibitors, may lead to weight loss due to increased glucose excretion through urine. Thiazolidinediones have been associated with weight gain, primarily due to fluid retention and fat accumulation. Sulfonylureas can also lead to weight gain as they stimulate insulin secretion, which may promote fat storage. Understanding these differences is crucial for tailoring diabetes treatment to individual patient needs, especially when considering their comorbidities such as obesity.